The DOI matches its Crossref record; 167 of the 167 references it cites were found in a registry or an index.
Update of Practice Guidelines for the Management of Community-Acquired Pneumonia in Immunocompetent Adults
Open accessAbstract
The Infectious Diseases Society of America (IDSA) produced guidelines for community-acquired pneumonia (CAP) in immunocompetent adults in 1998 and again in 2000 [1, 2]. Because of evolving resistance to antimicrobials and other advances, it was felt that an update should be provided every few years so that important developments could be highlighted and pressing questions answered. We addressed those issues that the committee believed were important to the practicing physician, including suggestions for initial empiric therapy for CAP. In some cases, only a few paragraphs were needed, whereas, in others, a somewhat more in-depth discussion was provided. Because many physicians focus on the tables rather than on the text of guidelines, it was decided that all of the information dealing with the initial empiric treatment regimens should be in tabular format with footnotes (tables 1–3). The topics selected for updating have been organized according to the headings used in the August 2000 CAP guidelines published in Clinical Infectious Diseases [2]. The major headings were “Epidemiology,” “Diagnostic Evaluation,” “Special Considerations,” “Management,” “Prevention,” and “Performance Indicators,” and each section had a number of subentries. Our current topics are either updates of specific subheadings or are new contributions, and the committee's recommendations are given at the beginning of each section. A summary of prior IDSA recommendations presented in 2000 and the updated and new recommendations can be found in table 4. Ratings of the strength of the supporting evidence and the quality of the data are given in parentheses after each recommendation, and the grading system used to categorize them is in table 5. The next guidelines for the treatment of CAP will be a joint effort by the IDSA and the American Thoracic Society (ATS). A working group representing both societies has been formed and is already at work on the next CAP treatment guidelines. Recommendation 1. The initial site of treatment should be based on a 3-step process: (1) assessment of preexisting conditions that compromise safety of home care; (2) calculation of the pneumonia PORT (Pneumonia Outcomes Research Team) Severity Index (PSI) with recommendation for home care for risk classes I, II, and III; and (3) clinical judgment (A-II). Recommendation 2. For discharge criteria, during the 24 h prior to discharge to the home, the patient should have no more than 1 of the following characteristics (unless this represents the baseline status): temperature, >37.8°C; pulse, >100 beats/min; respiratory rate, >24 breaths/min; systolic blood pressure, <90 mm Hg; blood oxygen saturation, <90%; and inability to maintain oral intake (B-I). Comment. Selection of the initial site of treatment, whether home or hospital, continues to be one of the most important clinical decisions made in the treatment of patients with CAP, often determining the selection and route of administration of antibiotic agents, intensity of medical observation, and use of medical resources. This decision is often made in the emergency department, the portal of entry for 75% of the 1 million annual pneumonia admissions in the United States. Two recent articles suggest that the initial site of treatment decision be selected using a systematic 3-step process [3, 4]. Step 1 involves assessment of any preexisting conditions that compromise the safety of home care, including severe hemodynamic instability, active coexisting conditions that require hospitalization, acute hypoxemia or chronic oxygen dependency, and inability to take oral medications. The second step involves calculation of the pneumonia PSI, with a recommendation for home care for patients in risk classes I, II, or III. A description of how the PSI is derived is shown in Appendix A. The third step involves clinical judgment regarding the overall health of the patient and the suitability for home care. Mitigating factors for step 3 include frail physical condition, severe social or psychiatric problems compromising home care (including a history of substance abuse), and an unstable living situation or homelessness. Clinical judgment should supercede decisions made on the basis of PSI alone. At the present time, 3 North American medical practice guidelines advocate use of the PSI as an objective measure of risk stratification to help determine the initial site of treatment for CAP [2, 5, 6]. Preliminary results from the Emergency Department Triage of Community-Acquired Pneumonia Study indicate that implementation of the PSI significantly increases the proportion of low-risk patients with pneumonia managed in the emergency department who are treated as outpatients without compromising outcomes, as measured by short-term mortality or subsequent hospitalization [7]. In this randomized, controlled study that involved 32 hospital emergency departments and >3200 patients with CAP, implementation of the PSI with high- and moderate-in
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2001) · PsycEXTRA Dataset · doi:10.1037/e548312006-001 · Cited by 5,011
Identification of a novel coronavirus in patients with severe acute respiratory syndrome
Drosten, C., Günther, S., Preiser, W., van der Werf, S., Brodt, H.-R., Becker, S., Rabenau, H., Panning, M., Kolesnikova, L., Fouchier, R. A. M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030747 · Cited by 4,574
A Novel Coronavirus Associated with Severe Acute Respiratory Syndrome
Ksiazek, T. G., Erdman, D., Goldsmith, C. S., Zaki, S. R., Peret, T., Emery, S., Tong, S., Urbani, C., Comer, J. A., Lim, W., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030781 · Cited by 4,344
Self-citationMortality Associated With Influenza and Respiratory Syncytial Virus in the United States
Thompson, W. W., Shay, D. K., Weintraub, E., Brammer, L., Cox, N., Anderson, L. J., & Fukuda, K. (2003) · JAMA · doi:10.1001/jama.289.2.179 · Cited by 3,673
A Major Outbreak of Severe Acute Respiratory Syndrome in Hong Kong
Lee, N., Hui, D., Wu, A., Chan, P., Cameron, P., Joynt, G. M., Ahuja, A., Yung, M. Y., Leung, C. B., To, K. F., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030685 · Cited by 2,628
Characterization of a Novel Coronavirus Associated with Severe Acute Respiratory Syndrome
Rota, P. A., Oberste, M. S., Monroe, S. S., Nix, W. A., Campagnoli, R., Icenogle, J. P., Peñaranda, S., Bankamp, B., Maher, K., Chen, M.-H., et al. (2003) · Science · doi:10.1126/science.1085952 · Cited by 2,474
Peiris, J., Chu, C., Cheng, V., Chan, K., Hung, I., Poon, L., Law, K., Tang, B., Hon, T., Chan, C., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13412-5 · Cited by 2,375
Practice Guidelines for the Management of Community-Acquired Pneumonia in Adults
Bartlett, J. G., Dowell, S. F., Mandell, L. A., File, T. M., Musher, D. M., & Fine, M. J. (2000) · Clinical Infectious Diseases · doi:10.1086/313954 · Cited by 2,286
Self-citationWhitney, C. G., Farley, M. M., Hadler, J., Harrison, L. H., Bennett, N. M., Lynfield, R., Reingold, A., Cieslak, P. R., Pilishvili, T., Jackson, D., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022823 · Cited by 2,228
Self-citationNiederman, M. S., Mandell, L. A., Anzueto, A., Bass, J. B., Broughton, W. A., Campbell, G. D., Dean, N., File, T., Fine, M. J., Gross, P. A., et al. (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.163.7.at1010 · Cited by 2,150
Self-citationSmallpox as a Biological Weapon: Medical and Public Health Management
Henderson, D. A., Inglesby, T. V., Bartlett, J. G., Ascher, M. S., Eitzen, E., Jahrling, P. B., Hauer, J., Layton, M., McDade, J., Osterholm, M. T., et al. (1999) · JAMA · doi:10.1001/jama.281.22.2127 · Cited by 1,541
Self-citationTularemia as a Biological Weapon: Medical and Public Health Management
Dennis, D. T., Inglesby, T. V., Henderson, D. A., Bartlett, J. G., Ascher, M. S., Eitzen, E., Fine, A. D., Friedlander, A. M., Hauer, J., Layton, M., et al. (2001) · JAMA · doi:10.1001/jama.285.21.2763 · Cited by 1,412
Self-citationIdentification of Severe Acute Respiratory Syndrome in Canada
Poutanen, S. M., Low, D. E., Henry, B., Finkelstein, S., Rose, D., Green, K., Tellier, R., Draker, R., Adachi, D., Ayers, M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030634 · Cited by 1,132
Holtzman, D. J., Powell‐Griner, E., Bolen, J. C., & Rhodes, L. (2000) · PubMed · Cited by 1,110
The Efficacy of Influenza Vaccine in Elderly Persons: A Meta-Analysis and Review of the Literature
Gross, P. A., Hermogenes, A. W., Sacks, H. S., Lau, J., & Levandowski, R. A. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-123-7-199510010-00008 · Cited by 1,100
The Protective Efficacy of Polyvalent Pneumococcal Polysaccharide Vaccine
Shapiro, E. D., Berg, A. T., Austrian, R., Schroeder, D., Parcells, V., Margolis, A., Adair, R. K., & Clemens, J. D. (1991) · New England Journal of Medicine · doi:10.1056/nejm199111213252101 · Cited by 1,051
Anthrax as a Biological Weapon, 2002: Updated Recommendations for Management
Inglesby, T. V., O'Toole, T., Henderson, D. A., Bartlett, J. G., Ascher, M. S., Eitzen, E., Friedlander, A. M., Gerberding, J., Hauer, J., Hughes, J., et al. (2002) · JAMA · doi:10.1001/jama.287.17.2236 · Cited by 1,027
Self-citationA Cluster of Cases of Severe Acute Respiratory Syndrome in Hong Kong
Tsang, K. W., Ho, P. L., Ooi, G. C., Yee, W. K., Wang, T., Chan-Yeung, M., Lam, W. K., Seto, W. H., Yam, L. Y., Cheung, T. M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030666 · Cited by 1,017
Treanor, J. J., Hayden, F. G., Vrooman, P. S., Barbarash, R., Bettis, R., Riff, D., Singh, S., Kinnersley, N., Ward, P., Mills, R. G., et al. (2000) · JAMA · doi:10.1001/jama.283.8.1016 · Cited by 1,014
(1997) · PsycEXTRA Dataset · doi:10.1037/e547512006-001 · Cited by 1,000
Bioterrorism-Related Inhalational Anthrax: The First 10 Cases Reported in the United States
Jernigan, J. A., Stephens, D. S., Ashford, D. A., Omenaca, C., Topiel, M. S., Galbraith, M., Tapper, M., Fisk, T. L., Zaki, S., Popovic, T., et al. (2001) · Emerging Infectious Diseases · doi:10.3201/eid0706.010604 · Cited by 999
Plague as a Biological Weapon: Medical and Public Health Management
Inglesby, T. V., Dennis, D. T., Henderson, D. A., Bartlett, J. G., Ascher, M. S., Eitzen, E., Fine, A. D., Friedlander, A. M., Hauer, J., Koerner, J. F., et al. (2000) · JAMA · doi:10.1001/jama.283.17.2281 · Cited by 997
Self-citationDecreased Susceptibility of Streptococcus pneumoniae to Fluoroquinolones in Canada
Chen, D. K., McGeer, A., de Azavedo, J. C., & Low, D. E. (1999) · New England Journal of Medicine · doi:10.1056/nejm199907223410403 · Cited by 987
Quality of Care, Process, and Outcomes in Elderly Patients With Pneumonia
Meehan, T. P. (1997) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1997.03550230056037 · Cited by 919
Marston, B. J. (1997) · Archives of Internal Medicine · doi:10.1001/archinte.1997.00440360129015 · Cited by 909
Fang, G.-D., Fine, M., Orloff, J., Arisumi, D., Yu, V. L., Kapoor, W., Grayston, J. T., Wang, S. P., Kohler, R., Muder, R. R., et al. (1990) · Medicine · doi:10.1097/00005792-199009000-00004 · Cited by 895
Community‐Acquired Pneumonia in Adults: Guidelines for Management
Bartlett, J. G., Breiman, R. F., Mandell, L. A., & File, Jr. (1998) · Clinical Infectious Diseases · doi:10.1086/513953 · Cited by 865
Self-citationCigarette Smoking and Invasive Pneumococcal Disease
Nuorti, J. P., Butler, J. C., Farley, M. M., Harrison, L. H., McGeer, A., Kolczak, M. S., & Breiman, R. F. (2000) · New England Journal of Medicine · doi:10.1056/nejm200003093421002 · Cited by 798
Houck, P. M., Bratzler, D. W., Nsa, W., Ma, A., & Bartlett, J. G. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.6.637 · Cited by 796
Self-citationKoch's postulates fulfilled for SARS virus
Fouchier, R. A. M., Kuiken, T., Schutten, M., van Amerongen, G., van Doornum, G. J. J., van den Hoogen, B. G., Peiris, M., Lim, W., Stöhr, K., & Osterhaus, A. D. M. E. (2003) · Nature · doi:10.1038/423240a · Cited by 789
Pallares, R., Liñares, J., Vadillo, M., Cabellos, C., Manresa, F., Viladrich, P. F., Martin, R., & Gudiol, F. (1995) · New England Journal of Medicine · doi:10.1056/nejm199508243330802 · Cited by 773
Carman, W. F., Elder, A. G., Wallace, L. A., McAulay, K., Walker, A., Murray, G. D., & Stott, D. J. (2000) · The Lancet · doi:10.1016/s0140-6736(99)05190-9 · Cited by 760
Nichol, K. L., Nordin, J., Mullooly, J., Lask, R., Fillbrandt, K., & Iwane, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa025028 · Cited by 752
Clinical signs and symptoms predicting influenza infection
Monto, A. S., Gravenstein, S., Elliott, M., Colopy, M., & Schweinle, J. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.21.3243 · Cited by 752
A Controlled Trial of a Critical Pathway for Treatment of Community-Acquired Pneumonia
Marrie, T. J. (2000) · JAMA · doi:10.1001/jama.283.6.749 · Cited by 731
Influenza virus neuraminidase inhibitors
Gubareva, L. V., Kaiser, L., & Hayden, F. G. (2000) · The Lancet · doi:10.1016/s0140-6736(99)11433-8 · Cited by 730
Carman, Elder, Wallace, & Mcaulay (2000) · The Lancet · Cited by 675
Pneumococcal polysaccharide vaccine efficacy. An evaluation of current recommendations
Butler, J. C. (1993) · JAMA · doi:10.1001/jama.270.15.1826 · Cited by 671
Mandell, L. A., Marrie, T. J., Grossman, R. F., Chow, A. W., Hyland, R. H., & and the Canadian Community-Acquired Pneumonia Working Group (2000) · Clinical Infectious Diseases · doi:10.1086/313959 · Cited by 664
Self-citationPotter, J., Stott, D. J., Roberts, M. A., Elder, A. G., O'Donnell, B., Knight, P. V., & Carman, W. F. (1997) · Journal of Infectious Diseases · doi:10.1093/infdis/175.1.1 · Cited by 660
Etiology of Community-Acquired Pneumonia: Impact of Age, Comorbidity, and Severity
RUIZ, M., EWIG, S., MARCOS, M. A., MARTINEZ, J. A., ARANCIBIA, F., MENSA, J., & TORRES, A. (1999) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.160.2.9808045 · Cited by 625
Heffelfinger, J. D. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.10.1399 · Cited by 610
Effectiveness of Pneumococcal Polysaccharide Vaccine in Older Adults
Jackson, L. A., Neuzil, K. M., Yu, O., Benson, P., Barlow, W. E., Adams, A. L., Hanson, C. A., Mahoney, L. D., Shay, D. K., & Thompson, W. W. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022678 · Cited by 608
Human Metapneumovirus Infections in Young and Elderly Adults
Falsey, A. R., Erdman, D., Anderson, L. J., & Walsh, E. E. (2003) · The Journal of Infectious Diseases · doi:10.1086/367901 · Cited by 595
Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997
(2000) · American Journal of Public Health · doi:10.2105/ajph.90.2.223 · Cited by 589
Impact of Respiratory Virus Infections on Persons With Chronic Underlying Conditions
Glezen, W. P. (2000) · JAMA · doi:10.1001/jama.283.4.499 · Cited by 559
Hayden, F. G., Treanor, J. J., Fritz, R. S., Lobo, M., Betts, R. F., Miller, M., Kinnersley, N., Mills, R. G., Ward, P., & Straus, S. E. (1999) · JAMA · doi:10.1001/jama.282.13.1240 · Cited by 550
Doern, G. V., Heilmann, K. P., Huynh, H. K., Rhomberg, P. R., Coffman, S. L., & Brueggemann, A. B. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.6.1721-1729.2001 · Cited by 538
Resistance to Levofloxacin and Failure of Treatment of Pneumococcal Pneumonia
Davidson, R., Cavalcanti, R., Brunton, J. L., Bast, D. J., de Azavedo, J. C. S., Kibsey, P., Fleming, C., & Low, D. E. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012122 · Cited by 533
Dowell, S. F., Peeling, R. W., Boman, J., Carlone, G. M., Fields, B. S., Guarner, J., Hammerschlag, M. R., Jackson, L. A., Kuo, C., Maass, M., et al. (2001) · Clinical Infectious Diseases · doi:10.1086/322632 · Cited by 528
Self-citationLim, W. S. (2001) · Thorax · doi:10.1136/thorax.56.4.296 · Cited by 525
The Looming Threat of Bioterrorism
Henderson, D. A. (1999) · Science · doi:10.1126/science.283.5406.1279 · Cited by 498
Gleason, P. P., Meehan, T. P., Fine, J. M., Galusha, D. H., & Fine, M. J. (1999) · Archives of Internal Medicine · doi:10.1001/archinte.159.21.2562 · Cited by 496
Stout, J. E., & Yu, V. L. (1997) · New England Journal of Medicine · doi:10.1056/nejm199709043371006 · Cited by 491
Case Definitions for Infectious Conditions Under Public Health Surveillance: (547492006-001)
(1997) · PsycEXTRA Dataset · doi:10.1037/e547492006-001 · Cited by 483
(2004) · PsycEXTRA Dataset · doi:10.1037/e548622006-001 · Cited by 471
Linezolid: The First Oxazolidinone Antimicrobial
Moellering, R. C. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-2-200301210-00015 · Cited by 455
Yu, V. L., Chiou, C. C. C., Feldman, C., Ortqvist, A., Rello, J., Morris, A. J., Baddour, L. M., Luna, C. M., Snydman, D. R., Ip, M., et al. (2003) · Clinical Infectious Diseases · doi:10.1086/377534 · Cited by 451
Influence of Age on Symptoms at Presentation in Patients With Community-Acquired Pneumonia
Metlay, J. P. (1997) · Archives of Internal Medicine · doi:10.1001/archinte.157.13.1453 · Cited by 418
Efficacy of Pneumococcal Vaccine in High-Risk Patients
Simberkoff, M. S., Cross, A. P., Al-Ibrahim, M., Baltch, A. L., Geiseler, P. J., Nadler, J., Richmond, A. S., Smith, R. P., Schiffman, G., Shepard, D. S., et al. (1986) · New England Journal of Medicine · doi:10.1056/nejm198611203152104 · Cited by 395
Örtqvist, Å., Hedlund, J., Burman, L.-Å., Elbel, E., Höfer, M., Leinonen, M., Lindblad, I., Sundelöf, B., & Kalin, M. (1998) · The Lancet · doi:10.1016/s0140-6736(97)07358-3 · Cited by 376
Hoban, D. J., Doern, G. V., Fluit, A. C., Roussel‐Delvallez, M., & Jones, R. N. (2001) · Clinical Infectious Diseases · doi:10.1086/320181 · Cited by 375
Risk factors for pneumonia in the elderly
Koivula, I., Sten, M., & Makela, P. H. (1994) · The American Journal of Medicine · doi:10.1016/0002-9343(94)90060-4 · Cited by 362
File, T. M., Segreti, J., Dunbar, L., Player, R., Kohler, R., Williams, R. R., Kojak, C., & Rubin, A. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.9.1965 · Cited by 360
Self-citationMartinez, J. A., Horcajada, J. P., Almela, M., Marco, F., Soriano, A., Garcia, E., Marco, M. A., Torres, A., & Mensa, J. (2003) · Clinical Infectious Diseases · doi:10.1086/367541 · Cited by 357
Loeb, M., McGeer, A., McArthur, M., Walter, S., & Simor, A. E. (1999) · Archives of Internal Medicine · doi:10.1001/archinte.159.17.2058 · Cited by 346
Anti-inflammatory effects of macrolide antibiotics
Čulić, O., Eraković, V., & Parnham, M. J. (2001) · European Journal of Pharmacology · doi:10.1016/s0014-2999(01)01321-8 · Cited by 334
Linezolid: The First Oxazolidinone Antimicrobial
Paterson, D. L., Pasculle, A. W., & McCurry, K. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-139-10-200311180-00017 · Cited by 328
Lonks, J. R., Garau, J., Gomez, L., Xercavins, M., Ochoa de Echagüen, A., Gareen, I. F., Reiss, P. T., & Medeiros, A. A. (2002) · Clinical Infectious Diseases · doi:10.1086/341978 · Cited by 324
Selection of Influenza Virus Mutants in Experimentally Infected Volunteers Treated with Oseltamivir
Gubareva, L. V., Kaiser, L., Matrosovich, M. N., Soo‐Hoo, Y., & Hayden, F. G. (2001) · The Journal of Infectious Diseases · doi:10.1086/318537 · Cited by 318
The Clinical Effectiveness of Pneumococcal Vaccine in the Elderly
SIMS, R. V., STEINMANN, W. C., MCCONVILLE, J. H., KING, L. R., ZWICK, W. C., & SCHWARTZ, J. S. (1988) · Annals of Internal Medicine · doi:10.7326/0003-4819-108-5-653 · Cited by 317
Macrolide Resistance Among Invasive <EMPH TYPE="ITAL">Streptococcus pneumoniae</EMPH> Isolates
Hyde, T. B. (2001) · JAMA · doi:10.1001/jama.286.15.1857 · Cited by 315
(1997) · PubMed · Cited by 305
Human Metapneumovirus as a Cause of Community-Acquired Respiratory Illness1
Stockton, J., Stephenson, I., Fleming, D., & Zambon, M. (2002) · Emerging Infectious Diseases · doi:10.3201/eid0809.020084 · Cited by 296
Muder, R. R. (1998) · The American Journal of Medicine · doi:10.1016/s0002-9343(98)00262-9 · Cited by 296
Kahn, K. L. (1990) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1990.03450150069033 · Cited by 293
Hansen, L. H., Mauvais, P., & Douthwaite, S. (1999) · Molecular Microbiology · doi:10.1046/j.1365-2958.1999.01202.x · Cited by 291
Wong, K. T., Antonio, G. E., Hui, D. S. C., Lee, N., Yuen, E. H. Y., Wu, A., Leung, C. B., Rainer, T. H., Cameron, P., Chung, S. S. C., et al. (2003) · Radiology · doi:10.1148/radiol.2282030593 · Cited by 289
Testing Strategies in the Initial Management of Patients with Community-Acquired Pneumonia
Metlay, J. P., & Fine, M. J. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-2-200301210-00012 · Cited by 286
Diagnosis ofLegionellaInfection
Murdoch, D. R. (2003) · Clinical Infectious Diseases · doi:10.1086/345529 · Cited by 270
A Large Outbreak of Legionnaires’ Disease at a Flower Show, the Netherlands, 1999
Den Boer, J. W., Yzerman, E. P. F., Schellekens, J., Lettinga, K. D., Boshuizen, H. C., Van Steenbergen, J. E., Bosman, A., Van den Hof, S., Van Vliet, H. A., Peeters, M. F., et al. (2002) · Emerging Infectious Diseases · doi:10.3201/eid0801.010176 · Cited by 270
Resistance to Macrolides and Related Antibiotics in Streptococcus pneumoniae
Leclercq, R., & Courvalin, P. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.9.2727-2734.2002 · Cited by 269
Gutierrez, F., Masia, M., Rodriguez, J. C., Ayelo, A., Soldan, B., Cebrian, L., Mirete, C., Royo, G., & Hidalgo, A. M. (2003) · Clinical Infectious Diseases · doi:10.1086/345852 · Cited by 268
Community‐Acquired Pneumonia Requiring Hospitalization: Is It Different in the Elderly?
Marrie, T. J., Haldane, E. V., Faulkner, R. S., Durant, H., & Kwan, C. (1985) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1985.tb01775.x · Cited by 264
Murdoch, D. R., Laing, R. T. R., Mills, G. D., Karalus, N. C., Town, G. I., Mirrett, S., & Reller, L. B. (2001) · Journal of Clinical Microbiology · doi:10.1128/jcm.39.10.3495-3498.2001 · Cited by 264
Antimicrobial Resistance of Streptococcus pneumoniae in the United States, 1979-1987
Spika, J. S., Facklam, R. R., Plikaytis, B. D., Oxtoby, M. J., & Pneumococcal Surveillance Working Group (1991) · Journal of Infectious Diseases · doi:10.1093/infdis/163.6.1273 · Cited by 261
Tait-Kamradt, A., Davies, T., Appelbaum, P. C., Depardieu, F., Courvalin, P., Petitpas, J., Wondrack, L., Walker, A., Jacobs, M. R., & Sutcliffe, J. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.12.3395-3401.2000 · Cited by 260
Battleman, D. S., Callahan, M., & Thaler, H. T. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.6.682 · Cited by 248
Martinez‐Sierra, C., Arizcorreta, A., Diaz, F., Roldan, R., Martin‐Herrera, L., Perez‐Guzman, E., & Giron‐Gonzalez, J. A. (2003) · Clinical Infectious Diseases · doi:10.1086/367643 · Cited by 244
Streptomycin and Alternative Agents for the Treatment of Tularemia: Review of the Literature
Enderlin, G., Morales, L., Jacobs, R. F., & Cross, J. T. (1994) · Clinical Infectious Diseases · doi:10.1093/clinids/19.1.42 · Cited by 234
Breakthrough Pneumococcal Bacteremia in Patients Being Treated with Azithromycin and Clarithromycin
Kelley, M. A., Weber, D. J., Gilligan, P., & Cohen, M. S. (2000) · Clinical Infectious Diseases · doi:10.1086/318157 · Cited by 234
Delay in appropriate therapy ofLegionella pneumonia associated with increased mortality
Heath, C. H., Grove, D. I., & Looke, D. F. M. (1996) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/bf01695659 · Cited by 230
Bacteremic pneumococcal pneumonia in one American city: a 20-year longitudinal study, 1978–1997
Mufson, M. A., & Stanek, R. J. (1999) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)00098-4 · Cited by 227
McCormick, A. W., Whitney, C. G., Farley, M. M., Lynfield, R., Harrison, L. H., Bennett, N. M., Schaffner, W., Reingold, A., Hadler, J., Cieslak, P., et al. (2003) · Nature Medicine · doi:10.1038/nm839 · Cited by 222
Self-citationCommunity-acquired pneumonia: impact of immune status.
Mundy, L. M., Auwaerter, P. G., Oldach, D., Warner, M. L., Burton, A., Vance, E., Gaydos, C. A., Joseph, J. M., Gopalan, R., & Moore, R. D. (1995) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.152.4.7551387 · Cited by 222
Thornsberry, C., Sahm, D. F., Kelly, L. J., Critchley, I. A., Jones, M. E., Evangelista, A. T., & Karlowsky, J. A. (2002) · Clinical Infectious Diseases · doi:10.1086/324525 · Cited by 222
Clinical Efficacy of Pneumococcal Vaccine in the Elderly
Koivula, I., Stén, M., Leinonen, M., & Mäkelä, P. H. (1997) · The American Journal of Medicine · doi:10.1016/s0002-9343(97)00149-6 · Cited by 217
Ho, P. L., Tse, W. S., Tsang, K. W. T., Kwok, T. K., Ng, T. K., Cheng, V. C. C., & Chan, R. M. T. (2001) · Clinical Infectious Diseases · doi:10.1086/319222 · Cited by 216
Instability on Hospital Discharge and the Risk of Adverse Outcomes in Patients With Pneumonia
Halm, E. A., Fine, M. J., Kapoor, W. N., Singer, D. E., Marrie, T. J., & Siu, A. L. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.11.1278 · Cited by 213
Bridges, C. B., Harper, S. A., Fukuda, K., Uyeki, T. M., Cox, N. J., & Singleton, J. A. (2002) · Jagiellonian University Repository (Jagiellonian University) · Cited by 213
Haake, D. A., Zakowski, P. C., Haake, D. L., & Bryson, Y. J. (1990) · Clinical Infectious Diseases · doi:10.1093/clinids/12.5.788 · Cited by 211
Antimicrobial-Drug Prescription in Ambulatory Care Settings, United States, 1992–2000
McCaig, L. F., Besser, R. E., & Hughes, J. M. (2003) · Emerging Infectious Diseases · doi:10.3201/eid0904.020268 · Cited by 210
Pérez-Trallero, E., Fernández-Mazarrasa, C., Garcı́a-Rey, C., Bouza, E., Aguilar, L., Garcı́a-de-Lomas, J., Baquero, F., & The Spanish Surveillance Group for Respiratory Pathogens (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.12.3334-3340.2001 · Cited by 210
Management of Community-Acquired Pneumonia
Halm, E. A., & Teirstein, A. S. (2002) · New England Journal of Medicine · doi:10.1056/nejmcp020499 · Cited by 205
Rodvold, K. A., Gotfried, M. H., Danziger, L. H., & Servi, R. J. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.6.1399 · Cited by 200
Emergence of Macrolide Resistance during Treatment of Pneumococcal Pneumonia
Musher, D. M., Dowell, M. E., Shortridge, V. D., Flamm, R. K., Jorgensen, J. H., Le Magueres, P., & Krause, K. L. (2002) · New England Journal of Medicine · doi:10.1056/nejm200202213460820 · Cited by 198
Self-citationDowell, S. F., Garman, R. L., Liu, G., Levine, O. S., & Yang, Y.-H. (2001) · Clinical Infectious Diseases · doi:10.1086/319205 · Cited by 197
Self-citationFinch, R., Schürmann, D., Collins, O., Kubin, R., McGivern, J., Bobbaers, H., Izquierdo, J. L., Nikolaides, P., Ogundare, F., Raz, R., et al. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.6.1746-1754.2002 · Cited by 181
Shortridge, V. D., Doern, G. V., Brueggemann, A. B., Beyer, J. M., & Flamm, R. K. (1999) · Clinical Infectious Diseases · doi:10.1086/313452 · Cited by 178
Jokinen, C., Heiskanen, L., Juvonen, H., Kallinen, S., Kleemola, M., Koskela, M., Leinonen, M., Ronnberg, P.-R., Saikku, P., Sten, M., et al. (2001) · Clinical Infectious Diseases · doi:10.1086/319746 · Cited by 178
Preventing pneumococcal bacteremia in patients at risk. Results of a matched case-control study
Farr, B. M. (1995) · Archives of Internal Medicine · doi:10.1001/archinte.155.21.2336 · Cited by 177
Pneumonia Acquired in the Community Through Drug-Resistant Streptococcus pneumoniae
EWIG, S., RUIZ, M., TORRES, A., MARCO, F., MARTINEZ, J. A., SANCHEZ, M., & MENSA, J. (1999) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.159.6.9808049 · Cited by 176
Chapman, L. E., Mertz, G. J., Peters, C. J., Jolson, H. M., Khan, A. S., Ksiazek, T. G., Koster, F. T., Baum, K. F., Rollin, P. E., Pavia, A. T., et al. (1999) · Antiviral Therapy · doi:10.1177/135965359900400404 · Cited by 170
Turett, G. S., Blum, S., Fazal, B. A., Justman, J. E., & Telzak, E. E. (1999) · Clinical Infectious Diseases · doi:10.1086/520209 · Cited by 156
Sisk, J. E., Whang, W., Butler, J. C., Sneller, V.-P., & Whitney, C. G. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-12-200306170-00007 · Cited by 155
Self-citationFluoroquinolone Resistance in Streptococcus pneumoniae in United States since 1994-1995
Brueggemann, A. B., Coffman, S. L., Rhomberg, P. R., Huynh, H. K., Almer, L. S., Nilius, A. M., Flamm, R. K., & Doern, G. V. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.3.680-688.2002 · Cited by 141
Update: Outbreak of severe acute respiratory syndrome--worldwide, 2003.
(2003) · PubMed · Cited by 140
Clinical Relevance of Macrolide-Resistant Streptococcus pneumoniae for Community-Acquired Pneumonia
Lynch, J. P., & Martínez, F. J. (2002) · Clinical Infectious Diseases · doi:10.1086/324527 · Cited by 132
Legionnaires' disease: a rational approach to therapy
Roig, J. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg191 · Cited by 131
Gay, K., Baughman, W., Miller, Y. K., et al. (2000) · The Journal of Infectious Diseases · doi:10.1086/315853 · Cited by 126
Oliveira, E. C., Marik, P. E., & Colice, G. (2001) · CHEST Journal · doi:10.1378/chest.119.6.1717 · Cited by 125
Doern, G. V. (2001) · Clinical Infectious Diseases · doi:10.1086/321847 · Cited by 124
Kaufman, P. (1947) · Archives of Internal Medicine · doi:10.1001/archinte.1947.00220110058004 · Cited by 123
Sahm, D. F., Karlowsky, J. A., Kelly, L. J., Critchley, I. A., Jones, M. E., Thornsberry, C., Mauriz, Y., & Kahn, J. B. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.4.1037-1042.2001 · Cited by 121
A Nosocomial Outbreak of Fluoroquinolone‐ResistantStreptococcus pneumoniae
Weiss, K., Restieri, C., Gauthier, R., Laverdière, M., McGeer, A., Davidson, R., Kilburn, L., Bast, D. J., de Azavedo, J., & Low, D. E. (2001) · Clinical Infectious Diseases · doi:10.1086/322658 · Cited by 115
[Clinical trial of an antipneumococcal vaccine in elderly subjects living in institutions].
GAILLAT, J., Zmirou‐Navier, D., Mallaret, M., Rouhan, D., Bru, J. P., Stahl, J. ‐., Delormas, P., & Micoud, M. (1985) · PubMed · Cited by 115
Harper, S. A., Fukuda, K., Cox, N. J., & Bridges, C. B. (2003) · PubMed · Cited by 107
Kaiser, L., Keene, O. N., Hammond, J., Elliott, M., & Hayden, F. G. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.21.3234 · Cited by 107
Frank, E., Liu, J., Kinasewitz, G. T., Moran, G. J., Oross, M., Olson, W. H., Reichl, V., Freitag, S., Bahal, N., Wiesinger, B. A., et al. (2002) · Clinical Therapeutics · doi:10.1016/s0149-2918(02)80034-0 · Cited by 99
Pneumonia Mortality Reduction and Quality Improvement in a Community Hospital
McGarvey, R. N., & Harper, J. J. (1993) · QRB - Quality Review Bulletin · doi:10.1016/s0097-5990(16)30605-4 · Cited by 97
Outbreak of Severe Acute Respiratory Syndrome—Worldwide, 2003
(2003) · JAMA · doi:10.1001/jama.289.14.1775 · Cited by 94
Antimicrobial Resistance among Clinical Isolates of Streptococcus pneumoniae in Canada during 2000
Low, D. E., de Azavedo, J., Weiss, K., Mazzulli, T., Kuhn, M., Church, D. L., Forward, K. R., Zhanel, G. G., Simor, A. E., & McGeer, A. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.5.1295-1301.2002 · Cited by 93
Fatal Pneumococcal Pneumonia Attributed to Macrolide Resistanceand Azithromycin Monotherapy
WATERER, G. W., Wunderink, R. G., & Jones, C. B. (2000) · CHEST Journal · doi:10.1378/chest.118.6.1839-a · Cited by 93
Kupronis, B. A., Richards, C. L., Whitney, C. G., & the Active Bacterial Core Surveillance Team (2003) · Journal of the American Geriatrics Society · doi:10.1046/j.1532-5415.2003.51501.x · Cited by 88
Self-citationIoannidis, J. P. A. (2001) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/48.5.677 · Cited by 88
Ortíz, G., Caballero‐Lopez, J., Friedland, I. R., Woods, G. L., Carides, A. D., & the Protocol 018 Ertapenem Community‐Acquired Pneumonia Study Group (2002) · Clinical Infectious Diseases · doi:10.1086/339543 · Cited by 87
Choi, E. H., & Lee, H. (1998) · Clinical Infectious Diseases · doi:10.1086/516340 · Cited by 83
Chapman, L. E., Ellis, B. A., Koster, F. T., Sotir, M., Ksiazek, T. G., Mertz, G. J., Rollin, P. E., Baum, K. F., Pavia, A. T., Christenson, J. C., et al. (2002) · Clinical Infectious Diseases · doi:10.1086/324619 · Cited by 79
Hagberg, L., Torres, A. F., Rensburg, D. J. V., Leroy, B., Rangaraju, M., & Ruuth, E. (2002) · Infection · doi:10.1007/s15010-002-2096-z · Cited by 77
Invasive Candidiasis: Turning Risk into a Practical Prevention Policy?
Sobel, J. D., & Rex, J. H. (2001) · Clinical Infectious Diseases · doi:10.1086/321812 · Cited by 74
Adegbola, R. A., Obaro, S., Biney, E., et al. (2001) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-200107000-00018 · Cited by 73
Sahm, D. F., Peterson, D. E., Critchley, I. A., & Thornsberry, C. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.9.2521-2524.2000 · Cited by 73
Outbreak of severe acute respiratory syndrome--worldwide, 2003.
(2003) · PubMed · Cited by 73
PNEUMOCOCCUS RESISTANT TO ERYTHROMYCIN AND LINCOMYCIN
Dixon, J. M. S. (1967) · The Lancet · doi:10.1016/s0140-6736(67)92150-2 · Cited by 72
Aubier, M., Verster, R., Regamey, C., Geslin, P., & Jb, V. (1998) · Clinical Infectious Diseases · doi:10.1086/516366 · Cited by 70
Bonacorsi, S., Scavizzi, M. R., Guiyoule, A., Amouroux, J., & Carniel, É. (1994) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.38.3.481 · Cited by 68
File, T. M. (2001) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/48.1.67 · Cited by 66
Self-citationEfficacy of doxycycline and ciprofloxacin against experimental Yersinia pestis infection
Russell, P. (1998) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/41.2.301 · Cited by 62
A Fresh Look at the Definition of Susceptibility of Streptococcus pneumoniae to β-Lactam Antibiotics
Musher, D. M., Bartlett, J. G., & Doern, G. V. (2001) · Archives of Internal Medicine · doi:10.1001/archinte.161.21.2538 · Cited by 59
Self-citationRosón, B., Carratalà, J., Tubau, F., Dorca, J., Liñares, J., Pallarés, R., Manresa, F., & Gudiol, F. (2001) · Microbial Drug Resistance · doi:10.1089/107662901750152864 · Cited by 57
Greenberg, S. B. (1991) · Infectious Disease Clinics of North America · doi:10.1016/s0891-5520(20)30408-6 · Cited by 57
Pullman, J. R., Champlin, J. J., & Vrooman, P. (2003) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2003.tb10511.x · Cited by 54
Clinical Features that Discriminate Inhalational Anthrax from Other Acute Respiratory Illnesses
Kuehnert, M. J., Doyle, T. J., Hill, H. A., Bridges, C. B., Jernigan, J. A., Dull, P. M., Reissman, D. B., Ashford, D. A., & Jernigan, D. B. (2003) · Clinical Infectious Diseases · doi:10.1086/346035 · Cited by 50
Gotfried, M. H., Dattani, D., Riffer, E., Devcich, K., Busman, T. A., Notario, G. F., & Palmer, R. N. (2002) · Clinical Therapeutics · doi:10.1016/s0149-2918(02)85148-7 · Cited by 49
Contopoulos‐Ioannidis, D. G. (2001) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/48.5.691 · Cited by 49
Musher, D. M., Mediwala, R., Phan, H. M., Chen, G. L., & BAUGHN, R. E. (2001) · Clinical Infectious Diseases · doi:10.1086/318709 · Cited by 43
Self-citationHowell, T. H. (1945) · Postgraduate Medical Journal · doi:10.1136/pgmj.21.230.20 · Cited by 41
Fogarty, C. M., Cyganowski, M., Palo, W. A., Hom, R. C., & Craig, W. A. (2002) · Clinical Therapeutics · doi:10.1016/s0149-2918(02)80084-4 · Cited by 38
The Role of Clonality in the Global Spread of Fluoroquinolone‐Resistant Bacteria
Klugman, K. P. (2003) · Clinical Infectious Diseases · doi:10.1086/367935 · Cited by 37
Hsueh, P., Teng, L., Wu, T.-L., Yang, D. I., Huang, W.-K., Shyr, J.-M., Chuang, Y.-C., Wan, J.-H., Yan, J.-J., Lu, J., et al. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.7.2145-2151.2003 · Cited by 37
Streptococcus pneumoniae,Brooklyn, New York: Fluoroquinolone Resistance at our Doorstep
Quale, J. M., Landman, D., Ravishankar, J., Flores, C., & Bratu, S. (2002) · Emerging infectious diseases · doi:10.3201/eid0806.010275 · Cited by 32
New Directions for Future Studies of Community-Acquired Pneumonia: Optimizing Impact on Patient Care
Vergis, E. N., & Yu, V. L. (1999) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s100960050418 · Cited by 30
Urinary detection of Streptococcus pneumoniae antigen for diagnosis of pneumonia.
Farina, C., Arosio, M. E. G., Vailati, F., et al. (2002) · PubMed · Cited by 30
Fluoroquinolone Treatment of Community-Acquired Pneumonia: A Meta-Analysis
Salkind, A. R., Cuddy, P. G., & Foxworth, J. W. (2002) · Annals of Pharmacotherapy · doi:10.1345/aph.1c167 · Cited by 28
McGeer, A., & Low, D. E. (2003) · Nature Medicine · doi:10.1038/nm0403-390 · Cited by 21
White, R. L., Enzweiler, K., Friedrich, L. V., Wagner, D. D., Hoban, D. J., & Bosso, J. A. (2002) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/s0732-8893(02)00391-7 · Cited by 17
Cited by
Mandell, L. A., Wunderink, R. G., Anzueto, A., Bartlett, J. G., Campbell, G. D., Dean, N. C., Dowell, S. F., File, T. M., Musher, D. M., Niederman, M. S., et al. (2007) · Clinical Infectious Diseases · doi:10.1086/511159 · Cited by 6,202
Self-citationClinical and economic burden of community-acquired pneumonia among adults in Europe
Welte, T., Torres, A., & Nathwani, D. (2012) · Thorax · doi:10.1136/thx.2009.129502 · Cited by 1,033
Pepin, J., Saheb, N., Coulombe, M.-A., Alary, M.-E., Corriveau, M.-P., Authier, S., Leblanc, M., Rivard, G., Bettez, M., Primeau, V., et al. (2005) · Clinical Infectious Diseases · doi:10.1086/496986 · Cited by 995
Epidemiology and Outcomes of Health-care–Associated Pneumonia
Kollef, M. H., Shorr, A., Tabak, Y. P., Gupta, V., Liu, L. Z., & Johannes, R. S. (2005) · Chest · doi:10.1378/chest.128.6.3854 · Cited by 948
Procalcitonin Guidance of Antibiotic Therapy in Community-acquired Pneumonia: A Randomized Trial
Christ-Crain, M., Stolz, D., Bingisser, R., Müller, C., Miedinger, D., Huber, P. R., Zimmerli, W., Harbarth, S., Tamm, M., & Müller, B. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200512-1922oc · Cited by 884
Metadata
- Authors
- Mandell, L. A., Bartlett, J. G., Dowell, S. F., File, T. M., Musher, D. M., & Whitney, C.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2003-12-01
- Volume
- 37
- Issue
- 11
- Pages
- 1405-1433
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2142230428
- Cited by
- 1,004
- References
- 167
- FWCI
- 98.87
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.